Relationship between pollen concentrations and short-acting ß2-agonist bronchodilator sales in central France: a daily time-series analysis over a 5-year period

Denis M. Caillaud, Sylvie Martin, Claire Ségala, Bertrand Evrard, Nihade Adrouche

Source: Eur Respir J, 54 (3) 1900271; 10.1183/13993003.00271-2019
Journal Issue: September
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Denis M. Caillaud, Sylvie Martin, Claire Ségala, Bertrand Evrard, Nihade Adrouche. Relationship between pollen concentrations and short-acting ß2-agonist bronchodilator sales in central France: a daily time-series analysis over a 5-year period. Eur Respir J, 54 (3) 1900271; 10.1183/13993003.00271-2019

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Relationship between pollen concentrations and shor-acting B2-agonists (SABA) bronchodilator sales in central France: a daily time-series analysis over a 5-year period.
Source: International Congress 2018 – Asthma: clinical screening tools
Year: 2018

Predictors of excessive short-acting beta2-agonist use and asthma exacerbations: a retrospective analysis of a Polish prescription database.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020


Effect of combined inhaled corticosteroid-formoterol therapy on short-acting beta2-agonist use in Poland: a retrospective analysis of pharmacy reports
Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Year: 2020


Prevalence of the use of oral corticosteroids in asthma – a 3-year analysis in Germany
Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies
Year: 2019

Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD
Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases
Year: 2019



Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Year: 2020




Safety of formoterol turbuhaler used as reliever in asthma: relationship with age and baseline treatment including regular long-acting β2-agonists (the RELIEF study)
Source: Eur Respir J 2002; 20: Suppl. 38, 44s
Year: 2002

Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021


Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening
Source: Eur Respir J 2001; 17: 1083-1088
Year: 2001



Outdoor mold spore levels and drug consumption for drug treated seasonal allergic rhino-conjunctivitis (TSAR): a 6-year study in France
Source: International Congress 2017 – Smoking, apnoea, infection, allergens and other factors
Year: 2017

Total costs according to reliever use of formoterol turbuhaler in asthma: results from the RELIEF worldwide randomized effectiveness study, stratified by maintenance medication levels
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

Three-year prospective cohort study of growth in asthmatic children prescribed appropriate inhaled corticosteroid (ICS) doses
Source: Eur Respir J 2004; 24: Suppl. 48, 614s
Year: 2004

Comparative analysis of asthma and COPD incidence in Serbia - a 10-year period
Source: Eur Respir J 2002; 20: Suppl. 38, 315s
Year: 2002

COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020


Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing – a 5-month study in Canada
Source: Eur Respir J 2003; 22: Suppl. 45, 411s
Year: 2003

Gender differences in the prevalence of severe asthma. Data from an island population database of high dose inhaled corticosteroid prescription
Source: Eur Respir J 2004; 24: Suppl. 48, 140s
Year: 2004

The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014


Asthma control in general practice with inhaled corticosteroids and long-acting B2-agonists administered as a fixed or free combination at stable dosage: the ALISE survey
Source: Eur Respir J 2002; 20: Suppl. 38, 397s
Year: 2002

Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 665s
Year: 2006

Adding montelukast versus doubling the budesonide dose in persistent asthma: a subgroup analysis of the COMPACT study
Source: Eur Respir J 2002; 20: Suppl. 38, 388s
Year: 2002